Related Experiment Videos
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug
N Osheroff1, A H Corbett, S H Elsea
1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146.
Cancer Chemotherapy and Pharmacology
|January 1, 1994
Summary
Four cancer drugs, including etoposide and amsacrine, target the same site on topoisomerase II (an enzyme crucial for DNA replication). This finding helps explain how these antineoplastic agents work.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Topoisomerase II (an enzyme essential for DNA replication and repair) is a key target for many cancer chemotherapy drugs.
- These drugs function by stabilizing an intermediate state where the enzyme cleaves DNA, leading to cell death.
- Despite a common mechanism, differences in how various drug classes affect enzyme activity have been observed.
Purpose of the Study:
- To investigate whether structurally diverse anticancer drugs targeting topoisomerase II interact at a common site or distinct sites on the enzyme.
- To elucidate the precise molecular interactions between topoisomerase II and different classes of antineoplastic agents.
Main Methods:
- Utilized competition experiments to assess drug interactions with topoisomerase II.
- Analyzed mechanistic differences in drug effects on DNA cleavage/religation, DNA strand passage, and ATP hydrolysis.
Main Results:
- Evidence strongly suggests that etoposide, amsacrine, genistein, and CP-115,953 interact within an overlapping domain on topoisomerase II.
- These structurally disparate drugs appear to share a common binding site or region on the target enzyme.
Conclusions:
- The findings indicate a shared interaction domain on topoisomerase II for multiple anticancer drugs, despite their structural differences.
- This shared site of action has significant implications for understanding drug mechanisms and developing new cancer therapies targeting topoisomerase II.